Interestingly, Dnmt3a-depleted CLL was sensitive to pharmacologic inhibition of Notch signaling in vitro and in vivo, supporting hyperactivation of Notch signaling in these cells and a high dependency on this pathway for survival. This evidence concerns the gene DNMT3A and B-cell chronic lymphocytic leukemia.